The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals
Open accessAbstract
Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related. However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day. To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims. First, using two pharmaceutical databases, we examined the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events. Second, we examined serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI. Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups. Among US prescription medicines, a statistically significant relationship was observed between daily dose of oral medicines and reports of liver failure ( P = 0.009), liver transplantation ( P < 0.001), and death caused by DILI ( P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal ( P = 0.10) or jaundice ( P = 0.16). Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day. A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, respectively, P = 0.03). Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI. More studies are needed to validate these observations and to explore their implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although idiosyncratic DILI typically is independent of the total dose or duration of medication administered, most implicated drugs are given at a daily dose of > 50–100 mg per day.33”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
Navarro, V. J., & Senior, J. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052270 · Cited by 811
Outcome and prognostic markers in severe drug‐induced liver disease†
Björnsson, E., & Olsson, R. (2005) · Hepatology · doi:10.1002/hep.20800 · Cited by 524
Benichou, C., Danan, G., & Flahault, A. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90102-7 · Cited by 491
Liver transplantation for acute liver failure from drug induced liver injury in the United States
Russo, M. W., Galanko, J. A., Shrestha, R., Fried, M. W., & Watkins, P. (2004) · Liver Transplantation · doi:10.1002/lt.20204 · Cited by 393
Idiosyncratic Drug Reactions: Current Understanding
Uetrecht, J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105150 · Cited by 304
Drug-induced liver injury: Summary of a single topic clinical research conference
Watkins, P. B., & Seeff, L. B. (2006) · Hepatology · doi:10.1002/hep.21095 · Cited by 279
Statins and hepatotoxicity: Focus on patients with fatty liver†
Chalasani, N. (2005) · Hepatology · doi:10.1002/hep.20671 · Cited by 265
Self-citation
Cited by
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Case definition and phenotype standardization in drug-induced liver injury
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944
Self-citationAndrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationStravitz, R. T., & Lee, W. M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31894-x · Cited by 844
Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Self-citationRUCAM in Drug and Herb Induced Liver Injury: The Update
Danan, G., & Teschke, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010014 · Cited by 729
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Abboud, G., & Kaplowitz, N. (2007) · Drug Safety · doi:10.2165/00002018-200730040-00001 · Cited by 479
Drug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 405
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
A Perspective on the Kinetics of Covalent and Irreversible Inhibition
Strelow, J. M. (2017) · SLAS Discovery · doi:10.1177/1087057116671509 · Cited by 392
Leise, M. D., Poterucha, J. J., & Talwalkar, J. A. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.09.016 · Cited by 356
Chen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Katarey, D., & Verma, S. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s104 · Cited by 331
Mechanisms of drug-induced liver injury
Yuan, L., & Kaplowitz, N. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.002 · Cited by 322
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
Lucena, M. I., Andrade, R. J., Kaplowitz, N., García‐Cortes, M., Fernández, M. C., Romero‐Gomez, M., Bruguera, M., Hallal, H., Robles‐Diaz, M., Rodriguez‐González, J. F., et al. (2009) · Hepatology · doi:10.1002/hep.22895 · Cited by 290
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Mechanisms of drug-induced liver injury: from bedside to bench
Tujios, S., & Fontana, R. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.22 · Cited by 277
Antidepressant-Induced Liver Injury: A Review for Clinicians
Voican, C. S., Corruble, E., Naveau, S., & Perlemuter, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13050709 · Cited by 275
Drug-induced autoimmune-like hepatitis
Czaja, A. J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1611-4 · Cited by 235
Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management
Björnsson, H., & Björnsson, E. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.035 · Cited by 212
Hepatotoxicity of statins and other lipid‐lowering agents
Björnsson, E. S. (2017) · Liver International · doi:10.1111/liv.13308 · Cited by 173
Incidence and risk factors of drug‐induced liver injury
Li, X., Tang, J., & Mao, Y. (2022) · Liver International · doi:10.1111/liv.15262 · Cited by 158
Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., & Aleo, M. D. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv152 · Cited by 148
Sundaram, V., & Björnsson, E. S. (2017) · Hepatology Communications · doi:10.1002/hep4.1088 · Cited by 138
Drug-induced liver injury: Is it somehow foreseeable?
Tarantino, G., Minno, M. N. D. D., & Capone, D. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2817 · Cited by 137
Drug-induced liver injury: a clinical update
Ghabril, M., Chalasani, N., & Björnsson, E. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283383c7c · Cited by 123
Self-citationHerbal hepatotoxicity: Clinical characteristics and listing compilation
Frenzel, C., & Teschke, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050588 · Cited by 122
Björnsson, H. K., Björnsson, E. S., Avula, B., Khan, I. A., Jonasson, J. G., Ghabril, M., Hayashi, P. H., & Navarro, V. (2020) · Liver International · doi:10.1111/liv.14393 · Cited by 125
Self-citationRisk of drug-induced liver injury from tumor necrosis factor antagonists
Björnsson, E. S., Gunnarsson, B. I., Gröndal, G., Jonasson, J. G., Einarsdottir, R., Ludviksson, B. R., Gudbjörnsson, B., & Olafsson, S. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.062 · Cited by 118
The Design of Covalent Allosteric Drugs
Nussinov, R., & Tsai, C.-J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124401 · Cited by 112
Review article: drug‐induced liver injury in clinical practice
Björnsson, E. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04320.x · Cited by 108
Lucena, M. I., Kaplowitz, N., Hallal, H., Castiella, A., García-Bengoechea, M., Otazua, P., Berenguer, M., Fernandez, M. C., Planas, R., & Andrade, R. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.041 · Cited by 89
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
Drug rechallenge following drug-induced liver injury
Hunt, C. M., Papay, J. I., Stanulovic, V., & Regev, A. (2017) · Hepatology · doi:10.1002/hep.29152 · Cited by 72
Teschke, R., Larrey, D., Melchart, D., & Danan, G. (2016) · Medicines · doi:10.3390/medicines3030018 · Cited by 69
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Kenna, J. G., Stahl, S. H., Eakins, J. A., Foster, A. J., Andersson, L. C., Bergare, J., Billger, M., Elebring, M., Elmore, C. S., & Thompson, R. A. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220491 · Cited by 48
“Autoimmune(-Like)” drug and herb induced liver injury: new insights into molecular pathogenesis
Sebode, M., Schulz, L., & Lohse, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091954 · Cited by 47
Sertraline hepatotoxicity: Report of a case and review of the literature
Collados, V., Hallal, H., & Andrade, R. J. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1192-7 · Cited by 33
Pek, S. L., Tavintharan, S., Woon, K., Lin, L., Ong, C. N., Lim, S. C., & Sum, C. F. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370215605588 · Cited by 26
Iruzubieta, P., Arias-Loste, M. T., Barbier-Torres, L., Martinez-Chantar, M. L., & Crespo, J. (2015) · BioMed Research International · doi:10.1155/2015/386186 · Cited by 24
Wang, Z., Liang, X., Yu, J., Zheng, X., Zhu, Y., Yan, Y., Dong, N., Di, L., Song, G., Zhou, X., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07131.x · Cited by 21
Drug‐Induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools
Dambach, D. M. (2014) · Predictive ADMET · doi:10.1002/9781118783344.ch19 · Cited by 4
Metadata
- Authors
- Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., & Chalasani, N.
- Venue
- Hepatology
- Published
- 2008-06
- Volume
- 47
- Issue
- 6
- Pages
- 2003-2009
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1969780974
- Cited by
- 389
- References
- 13
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.